Xenon Pharmaceuticals (NASDAQ:XENE) Stock Rating Upgraded by Wall Street Zen

Xenon Pharmaceuticals (NASDAQ:XENE) was upgraded by Wall Street Zen from a “strong sell” rating to a “sell” rating in a research report issued to clients and investors on Saturday.

A number of other analysts also recently weighed in on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Xenon Pharmaceuticals in a research report on Monday, July 6th. JPMorgan Chase & Co. increased their price target on shares of Xenon Pharmaceuticals from $80.00 to $82.00 and gave the company an “overweight” rating in a research report on Wednesday, May 27th. Wells Fargo & Company reiterated an “overweight” rating and set a $69.00 price target on shares of Xenon Pharmaceuticals in a research report on Sunday, May 10th. Royal Bank Of Canada boosted their price objective on shares of Xenon Pharmaceuticals from $80.00 to $82.00 and gave the stock an “outperform” rating in a report on Friday, May 8th. Finally, Needham & Company LLC cut their price objective on shares of Xenon Pharmaceuticals from $80.00 to $78.00 and set a “buy” rating for the company in a research note on Friday, May 8th. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $77.20.

Xenon Pharmaceuticals Price Performance

XENE opened at $62.67 on Friday. The business’s fifty day simple moving average is $59.30 and its 200 day simple moving average is $53.49. Xenon Pharmaceuticals has a 52 week low of $30.00 and a 52 week high of $72.66. The stock has a market cap of $6.06 billion, a PE ratio of -13.33 and a beta of 0.62.

Xenon Pharmaceuticals (NASDAQ:XENE) last issued its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported ($1.17) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($1.17). During the same period in the prior year, the business posted ($0.83) EPS. As a group, equities analysts anticipate that Xenon Pharmaceuticals will post -4.92 earnings per share for the current year.

Insider Activity

In related news, Director Gary Patou sold 1,322 shares of the firm’s stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $53.14, for a total transaction of $70,251.08. Following the transaction, the director directly owned 24,896 shares in the company, valued at $1,322,973.44. This trade represents a 5.04% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Gillian Cannon sold 1,190 shares of Xenon Pharmaceuticals stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $53.14, for a total value of $63,236.60. Following the completion of the transaction, the director directly owned 1,455 shares in the company, valued at $77,318.70. This trade represents a 44.99% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Corporate insiders own 2.91% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Danske Bank A S purchased a new position in shares of Xenon Pharmaceuticals in the third quarter worth $32,000. Blue Trust Inc. boosted its position in Xenon Pharmaceuticals by 2,560.7% during the 4th quarter. Blue Trust Inc. now owns 745 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 717 shares during the period. Kestra Advisory Services LLC purchased a new stake in Xenon Pharmaceuticals during the 4th quarter valued at $33,000. Osaic Holdings Inc. grew its holdings in Xenon Pharmaceuticals by 541.4% in the 2nd quarter. Osaic Holdings Inc. now owns 1,225 shares of the biopharmaceutical company’s stock worth $40,000 after acquiring an additional 1,034 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd bought a new stake in Xenon Pharmaceuticals in the 4th quarter worth $43,000. Institutional investors own 95.45% of the company’s stock.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.